IRIS
FANIN, Renato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.318
AS - Asia 11.078
EU - Europa 8.001
SA - Sud America 2.293
Continente sconosciuto - Info sul continente non disponibili 1.128
AF - Africa 289
OC - Oceania 14
Totale 54.121
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.630
SG - Singapore 5.050
CN - Cina 2.412
UA - Ucraina 2.129
BR - Brasile 1.763
IT - Italia 1.146
DE - Germania 1.142
HK - Hong Kong 1.138
VN - Vietnam 805
FI - Finlandia 798
RU - Federazione Russa 624
SE - Svezia 522
FR - Francia 521
IE - Irlanda 387
CA - Canada 351
GB - Regno Unito 289
IN - India 262
TR - Turchia 246
BD - Bangladesh 245
AR - Argentina 184
KR - Corea 171
IQ - Iraq 114
CO - Colombia 99
MX - Messico 91
ZA - Sudafrica 82
ID - Indonesia 78
EC - Ecuador 69
PL - Polonia 69
PK - Pakistan 64
NL - Olanda 56
ES - Italia 55
JP - Giappone 53
IL - Israele 45
UZ - Uzbekistan 45
VE - Venezuela 45
AT - Austria 44
IR - Iran 43
SA - Arabia Saudita 39
CR - Costa Rica 37
MA - Marocco 35
CZ - Repubblica Ceca 34
PY - Paraguay 32
CL - Cile 31
JM - Giamaica 31
AE - Emirati Arabi Uniti 30
MY - Malesia 30
PE - Perù 29
PH - Filippine 29
TT - Trinidad e Tobago 29
KE - Kenya 27
NI - Nicaragua 27
BE - Belgio 25
HN - Honduras 25
EG - Egitto 23
GT - Guatemala 23
PR - Porto Rico 22
LT - Lituania 21
NP - Nepal 21
KZ - Kazakistan 20
TG - Togo 20
TN - Tunisia 20
UY - Uruguay 20
BO - Bolivia 19
EU - Europa 18
JO - Giordania 18
RO - Romania 18
GR - Grecia 15
SC - Seychelles 15
TH - Thailandia 15
RS - Serbia 14
SV - El Salvador 14
CW - ???statistics.table.value.countryCode.CW??? 13
ET - Etiopia 13
KG - Kirghizistan 13
OM - Oman 13
AU - Australia 12
AL - Albania 11
PS - Palestinian Territory 11
AZ - Azerbaigian 10
CH - Svizzera 10
LB - Libano 10
DZ - Algeria 9
GE - Georgia 9
GP - Guadalupe 9
LV - Lettonia 9
PT - Portogallo 9
DO - Repubblica Dominicana 8
EE - Estonia 8
BG - Bulgaria 7
BH - Bahrain 6
HU - Ungheria 6
LK - Sri Lanka 6
AO - Angola 5
GA - Gabon 5
LU - Lussemburgo 5
PA - Panama 5
QA - Qatar 5
CG - Congo 4
KH - Cambogia 4
RW - Ruanda 4
Totale 52.932
Salva come PNG Salva come JPEG
Città #
Fairfield 2.993
Woodbridge 2.896
Ashburn 2.498
Houston 2.008
Singapore 1.945
Ann Arbor 1.894
San Jose 1.631
Jacksonville 1.423
Seattle 1.228
Beijing 1.182
Wilmington 1.132
Hong Kong 1.130
Chandler 1.109
Council Bluffs 1.002
Cambridge 983
Dearborn 891
Boardman 529
Dallas 394
Princeton 385
Dublin 384
Lauterbourg 375
Los Angeles 359
Udine 284
Santa Clara 257
Ho Chi Minh City 250
Buffalo 209
San Diego 194
Hefei 179
São Paulo 179
New York 174
Izmir 170
Hanoi 160
Seoul 153
Munich 129
Helsinki 118
Redondo Beach 111
Milan 104
Ogden 101
Ottawa 100
North Bergen 91
The Dalles 91
Norwalk 89
Des Moines 87
Dong Ket 84
Phoenix 80
Frankfurt am Main 73
Toronto 69
Montreal 68
Trieste 68
Orem 66
Warsaw 62
Chicago 59
Rio de Janeiro 56
Turku 56
Nanjing 55
Mumbai 54
Atlanta 52
Redmond 50
Pittsburgh 47
Tokyo 47
Nuremberg 46
Kunming 41
London 41
Baghdad 40
Chennai 40
Rome 40
Tashkent 40
Brooklyn 37
Denver 36
Johannesburg 36
Belo Horizonte 34
Brasília 34
Stockholm 34
Guangzhou 33
Boston 32
Da Nang 31
Dhaka 30
Philadelphia 30
Bogotá 29
Regensburg 29
Simi Valley 29
Haiphong 28
San Francisco 28
Curitiba 27
Mexico City 27
Poplar 27
Las Vegas 26
Jinan 25
Quito 25
San José 25
Brussels 24
Managua 24
Miami 24
Porto Alegre 24
Shanghai 24
Amsterdam 23
Guayaquil 23
Hangzhou 23
Nairobi 23
Nanchang 23
Totale 33.862
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 288
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 253
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 234
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 228
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 225
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 221
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 217
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 217
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 216
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 211
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 206
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 205
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study 204
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 204
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 203
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 200
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 199
Atypical haemolytic-uraemic syndrome at the onset of acute promyelocytic leukaemia. 196
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 195
A comparison of allografting with autografting for newly diagnosed myeloma 195
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 193
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 193
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 192
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 192
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 192
Multipotent Progenitor Cells Are Present in Human Peripheral Blood. 192
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 191
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 189
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 188
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells 188
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 187
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 187
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 187
P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. 185
Multipotent Mesenchymal Stem Cells Can Be Isolated and Grown from Many Tissues (Bone Marrow, Liver and Heart) 185
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 184
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 184
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 183
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 182
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 182
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 180
Family history of cancer and risk of second malignancies in young cancer patients in Trieste, Italy. 179
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 179
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 179
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 179
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 178
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 177
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 177
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 175
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 175
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 174
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles? 174
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 173
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 173
Management of immune thrombocytopenia in elderly patients 173
Epstein-Barr virus (EBV) reactivation in a patient treated with ATG for severe aplastic anemia 171
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 171
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 171
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 171
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 170
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 169
“Overexpression of multidrug resistance-associated P-170 glycoprotein in acute non lymphocytic leukemia”. 167
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation 167
Pre-Chemotherapy risk factors for invasive fungal diseases: Prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (seifem 2010-a multicenter study) 167
Rituximab for the treatment of type II mixed cryoglobulinemia. 166
Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience 166
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome. 165
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 165
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. 165
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 165
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 165
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 165
Granulocyte-macrophage colony -stimulating factor in acute nonlymphocytic leukemia before and after chemo therapy”. 164
Autologous stem cell transplantation in chronic carriers of hepatitis B virus and hepatitis C virus affected by onco-hematologic diseases. 164
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 163
Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). 163
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 163
Acute promyelocytic leucemia: low expression of multidrug resistance phenotype at onset suggest a favourable effect of gentuzumab ozogamicyn (CMA-676 162
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. 162
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. 162
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 161
Late onset cytomegalovirus encephalitis after reduced-intensity conditioning allogeneic SCT: an emerging neurological complication? 161
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 161
The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. 160
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 160
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 160
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 160
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 160
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 159
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 159
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 159
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. 158
Unexpected phenotype of a typical NPM1 mutant 158
Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes. 157
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 157
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 157
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 157
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. 156
Multiple Myeloma: presenting features and survival according to hospital referral 156
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 156
Totale 18.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.313
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.313
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.238 0 0 0 0 93 144 185 143 56 507 634 476
2022/20232.817 419 159 31 328 259 829 14 207 384 37 86 64
2023/2024853 122 66 27 27 132 100 17 53 142 65 32 70
2024/20256.868 149 502 381 170 292 309 407 426 665 603 1.093 1.871
2025/202613.484 1.008 1.468 1.119 1.335 1.865 1.070 1.584 436 1.010 1.271 809 509
2026/20274.539 340 837 1.236 1.895 231 0 0 0 0 0 0 0
Totale 54.121